ArticleBMC neurology2026
Concurrent phenylketonuria and immune-mediated central nervous system involvement: a case report highlighting rare co-occurrence.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWhite-matter abnormalities are common in phenylketonuria (PKU) and are typically attributed to metabolic hypomyelination or intramyelinic edema. Immune-mediated CNS involvement co-occurring with PKU has rarely been described in adults. CASE: An 18-year-old male university freshman diagnosed with classical PKU presented with a 3-week history characterized by progressive bilateral lower-limb weakness and gait instability. Cervical spinal magnetic resonance imaging (MRI) revealed intramedullary lesions, indicating possible immune-mediated CNS involvement overlapping PKU. Cerebrospinal fluid (CSF) analysis was acellular but demonstrated positive oligoclonal IgG bands. Notable clinical and radiological improvement was observed following the administration of high-dose intravenous methylprednisolone. DIAGNOSIS: Considering the acute course, brain cord involvement, positive OCB, and steroid responsiveness, an acute immune-mediated CNS lesion overlapping PKU was diagnosed. The symmetric diffusion‑restricted brain lesions raised the possibility of concomitant PKU‑related intramyelinic edema. TREATMENT: High‑dose intravenous methylprednisolone (1 g/day for 3 days) followed by an oral taper was administered, together with strict low‑phenylalanine diet and vitamin supplementation. OUTCOME: Cognitive slowing and lower‑limb weakness improved substantially within 3 weeks. One‑month follow‑up MRI showed regression of spinal lesions and slight reduction of supratentorial white‑matter abnormalities.
conclusionsThis case highlights a potential metabolic–immune overlap in PKU. Positive OCB and steroid‑responsive cord lesions support an inflammatory component, while symmetric diffusion‑restricted brain lesions suggest concurrent metabolic vulnerability. Longitudinal imaging and metabolic control (serial plasma phenylalanine/tyrosine, myelin‑sensitive MRI metrics) are essential to refine diagnosis and guide the need for disease‑modifying therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.